Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Personalized Cancer Insights, Grounded in Biology, DNA/RNA & AI Delivered in an Average of 10 Days


      News provided by

      First Ascent Biomedical

      Nov 10, 2025, 08:16 ET

      Share this article

      Share this article


      In cancer care, every day that passes can cost a life. First Ascent Biomedical is racing against that clock. By testing a patient's live cancer cells outside the body, the company reveals how their unique biology responds to FDA-approved drugs and combinations before treatment begins, delivering personalized options in an average of ten days before cancer has a chance to advance.

      MIAMI, Nov. 10, 2025 /PRNewswire/ -- The standard of care in cancer, adopted in the 1990s, is built on consensus based clinical research over large patient populations. However, if we know biologically each person is unique, then a consensus-based treatment plan may not work. DNA and RNA sequencing, biomarker identification, and targeted therapies began being offered to cancer patients in the late 1990s and early 2000s and can take weeks.  Each patient's unique biology demands a personalized cancer treatment because cancer does not wait.

      Continue Reading
      “Cancer doesn’t pause while we wait for lab results, so we built a system that doesn’t pause either.”
      “Cancer doesn’t pause while we wait for lab results, so we built a system that doesn’t pause either.”

      First Ascent Biomedical is changing this timeline. Its Functional Precision Medicine (FPM) platform combines functional drug validation, DNA/RNA sequencing, and AI providing personalized cancer treatment insights that have been previously unattainable. All the data starts with the patient, testing each individual's live cancer cells outside the body before treatment starts to see exactly how their tumor responds to FDA-approved drugs and combinations. These real-world biological results are then integrated with genomic sequencing and AI analysis to pinpoint the treatments most likely to succeed for that person's unique cancer biology, delivering actionable, personalized options in an average of ten days.

      By bringing biology and genomics together, First Ascent Biomedical transforms consensus-based possibility into proof, helping oncologists choose the right treatment before cancer has a chance to advance.

      "Cancer doesn't pause while we wait for lab results," said Jim Foote, co-founder of First Ascent. "So, we built a system that doesn't pause either."

      Enhancing the Promise of Genomics
      By testing a patient's live tumor cells against more than 150 FDA-approved drugs and combinations, we validate what drugs work, and which ones do not. When that data is integrated with DNA/RNA sequencing, First Ascent gives oncologists evidence they can act on, not just data to consider. (1) In doing so, it directly addresses the biggest questions physicians, hospital systems, and patients are asking in the era of precision oncology, the personalized data.

      One of the most common and persistent misconceptions in oncology is that functional precision medicine replaces genomics. It does not. In fact, it combines the power of FPM, genomics, and AI. As First Ascent's Head of Commercial Operations, Andria Parks explains, "Genomics is the sheet music. Functional Precision Medicine is the orchestra, and AI is the conductor. Our platform brings the biology to life, showing how a patient's tumor actually responds to treatment, not just how it might respond on paper."

      This is a crucial distinction for clinicians and institutions. Functional testing does not disrupt current workflows; it enhances them. Live-cell results can be reported alongside sequencing insights in a standard tumor board setting. This allows Oncologists to use functional data to prioritize therapies, avoid non-responders, and support off-label use with real-world tumor response evidence and data.

      Fast, Scalable, and Validated
      For years, FPM was considered too slow or too niche for widespread clinical use. That is no longer the case. Through automation, robotics, and proprietary cell enrichment technology, First Ascent's platform delivers results in a clinically actionable timeframe, an average of 10 days, fast enough to guide the next treatment decision and precise enough to provide:

      • Validated response improvement: 83% of patients responded better to treatments identified through FPM. (1)
      • Durability of response: Patients remained cancer-free 8.5 times longer compared to their previous therapies. (1)
      • Clinical readiness: All testing is performed under CLIA-certified lab conditions and validated in peer-reviewed publications, including Nature Medicine. (1)

      This combination of speed, precision and validation allows oncologists to move beyond probabilities and population-level, consensus-based models alone. With First Ascent's AI-driven analysis, they now gain access to real-time drug sensitivity data synthesized with genomics and prior clinical knowledge to surface optimal treatments faster than ever before.

      Speed Improves Outcomes
      The impact for patients is significant: fewer side effects from ineffective drugs, fewer months lost to trial-and-error, and more time to act while the disease is still controllable. For families, faster insights mean more moments together, more confidence in treatment decisions, and more hope, even in the hardest cases. 

      Take Logan, a young patient whose cancer defied standard treatments. His tumor showed no clear genetic path forward. But when his live cells were tested through First Ascent's platform, an unexpected drug combination emerged, one not indicated by genomics alone. With that functional evidence in hand, his care team made an immediate switch, while eliminating a drug that was ineffective but potentially very damaging to his body. Today, Logan is healthy, active, and cancer-free. (2)

      And FPM is no longer a tool just for patients at the end of the road. Increasingly, physicians are leveraging the platform at first relapse, using it to avoid wasted time and prevent irreversible progression. (3)

      Powered by AI, Built for the Future
      AI plays a vital role in making FPM both powerful and scalable. By integrating functional drug-response data with DNA/RNA data, AI can:

      • Rank likely responders
      • Predict resistance patterns
      • Discover new drug combinations
      • Identify biomarkers to guide future care

      "As our dataset grows, so does our platform's intelligence and our ability to help physicians make smarter, faster decisions across more tumor types and care settings," said Andria Parks, Head of Commercial Operations at First Ascent Biomedical. "We're making functional precision oncology accessible to every patient, everywhere by bringing personalized, evidence-based insights to the point of care when time matters most."

      About First Ascent Biomedical
      First Ascent Biomedical is revolutionizing cancer treatment with its AI-driven Drug Prediction Platform. By integrating DNA/RNA sequencing, mutation analysis, and drug sensitivity testing, we can identify personalized therapies for all solid and liquid tumors. Using proprietary cell enrichment technology, our platform rapidly tests hundreds of FDA-approved drugs, delivering actionable treatment plans to physicians in an average of 10 days. Studies show our platform extends patient survival, provides more real treatment options than DNA-only testing, and has the potential to improve outcomes, patient response, and healthcare costs by avoiding ineffective therapies.

      Our first-in-kind product, xDRIVE, and DxPP Platforms deliver the First Ascent difference.

      For more information, visit firstascendbiomedical.com 

      References 

      1. Azzam, Diana, Dr., et al. "The Clinical Utility and Accessibility of Functional Precision Medicine for Relapsed/Refractory Pediatric and Adult Cancers." Nature Medicine, Published:11 April 2024. Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL. 
      2. "TEDxMiami." TEDx Talks Featuring Dr. Diana Azzam, TED Conferences, 5 May 2023, ted.com/tedx/events/12345.
      3. Caffrey, Mary. "Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy." The American Journal of Managed Care, vol. 30, no. 3, 14 Feb. 2024, p. SP238. AJMC, ajmc.com/view/genomic-testing-is-worth-the-wait-when-balanced-against-cost-of-the-wrong-therapy.

      Media Contact:
      Karla Jo Helms
      JOTO PR™
      727-777-4629
      jotopr.com

      SOURCE First Ascent Biomedical

      Modal title

      Also from this source

      First Ascent Biomedical Names Dr. Gilberto Lopes Chairman of Its Medical Advisory Board

      First Ascent Biomedical Names Dr. Gilberto Lopes Chairman of Its Medical Advisory Board

      First Ascent Biomedical, a precision oncology company developing biology-driven cancer treatment decision support, today announced the appointment of ...

      Raymond Rodriguez-Torres Appointed First Ascent Biomedical New President to Scale Functional Precision Oncology

      Raymond Rodriguez-Torres Appointed First Ascent Biomedical New President to Scale Functional Precision Oncology

      First Ascent Biomedical announced that its Board of Directors has unanimously appointed Raymond Rodriguez-Torres as President, marking a significant...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Artificial Intelligence

      Artificial Intelligence

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.